Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Alterations in Serum Inflammatory Markers and Fecal Microbiota Following Administration of the Probiotic Formulation VSL#3 in Patients With Nonalcoholic Fatty Liver Disease

NCT03511365 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT03511365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03511365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Alterations in Serum Inflammatory Markers and Fecal Microbiota Following Administration of the Probiotic Formulation VSL#3 in Patients With Nonalcoholic Fatty Liver Disease
Lead sponsor
Northwell Health
Phase
Phase 1/2
Overall status
Terminated
Start date
May 15, 2018
Completion date
October 11, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

interleukin-17 mesh descriptor data 2018, non-alcoholic fatty liver disease, probiotics mesh descriptor data 2018